Template:Relative oral potencies of estrogens
Jump to navigation
Jump to search
| Estrogen | HF | VE | UCa | FSH | LH | HDL-C | SHBG | CBG | AGT | Liver |
|---|---|---|---|---|---|---|---|---|---|---|
| Estradiol | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| Estrone | ? | ? | ? | 0.3 | 0.3 | ? | ? | ? | ? | ? |
| Estriol | 0.3 | 0.3 | 0.1 | 0.3 | 0.3 | 0.2 | ? | ? | ? | 0.67 |
| Estrone sulfate | ? | 0.9 | 0.9 | 0.8–0.9 | 0.9 | 0.5 | 0.9 | 0.5–0.7 | 1.4–1.5 | 0.56–1.7 |
| Conjugated estrogens | 1.2 | 1.5 | 2.0 | 1.1–1.3 | 1.0 | 1.5 | 3.0–3.2 | 1.3–1.5 | 5.0 | 1.3–4.5 |
| Equilin sulfate | ? | ? | 1.0 | ? | ? | 6.0 | 7.5 | 6.0 | 7.5 | ? |
| Ethinylestradiol | 120 | 150 | 400 | 60–150 | 100 | 400 | 500–600 | 500–600 | 350 | 2.9–5.0 |
| Diethylstilbestrol | ? | ? | ? | 2.9–3.4 | ? | ? | 26–28 | 25–37 | 20 | 5.7–7.5 |
Sources and footnotes
Notes: Values are ratios, with estradiol as standard (i.e., 1.0). Abbreviations: HF = Clinical relief of hot flashes. VE = Increased proliferation of vaginal epithelium. UCa = Decrease in UCa. FSH = Suppression of FSH levels. LH = Suppression of LH levels. HDL-C, SHBG, CBG, and AGT = Increase in the serum levels of these liver proteins. Liver = Ratio of liver estrogenic effects to general/systemic estrogenic effects (hot flashes/gonadotropins). Sources: [1][2][3][4][5][6][7][8][9][10] | ||||||||||
Template documentationSee also
References
- ↑ Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947.
- ↑ Göretzlehner G (1990). "Wirkspektrum unterschiedlicher Östrogene". In Wolf AS, Schneider HP (eds.). Östrogene in Diagnostik und Therapie (in Deutsch). Springer-Verlag. pp. 78–. ISBN 978-3-642-75101-1.
- ↑ Kaufmann M, Costa SD, Scharl A, eds. (2013). Die Gynäkologie (in Deutsch). Springer-Verlag. pp. 105–. ISBN 978-3-662-11496-4.
- ↑ Kuhl, H. (April 1997). "Metabolische Effekte der Östrogene und Gestagene" [Metabolic Effects of Estrogens and Progestogens]. Der Gynäkologe (in Deutsch). 30 (4): 357–369. doi:10.1007/PL00003042. ISSN 0017-5994.
- ↑ Ellerington MC, Whitcroft SI, Whitehead MI (1994). "Therapeutic and Preventive Aspects of Estrogen and Progesterone Therapy". In Lorrain J, Plouffe L Jr, Ravnikar VA, Speroff L, Watts NB (eds.). Comprehensive Management of Menopause. pp. 269–285. doi:10.1007/978-1-4612-4330-4_26. ISBN 978-1-4612-4330-4. ISSN 0178-0328.
- ↑ van Keep PA, Utian WH, Vermeulen A (1982). van Keep PA, Utian WH, Vermeulen A (eds.). Potency and hepato-cellular effects of oestrogens after oral, percutaneous, and subcutaneous administration. Third International Congress on the Menopause, held in Ostend, Belgium, in June 1981, under the auspices of the International Menopause Society. The Controversial Climacteric. pp. 103–125. doi:10.1007/978-94-011-7253-0_12. ISBN 978-94-011-7253-0.
- ↑ Watts DA, Sharp HT, Peterson CM (2003). "Primary and Secondary Hypogonadism in Women". In Meikle AW (ed.). Endocrine Replacement Therapy in Clinical Practice. Springer Science & Business Media. pp. 471–505. doi:10.1007/978-1-59259-375-0_25. ISBN 978-1-59259-375-0.
- ↑ Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenner PF, Mishell DR (November 1982). "Comparison of pharmacodynamic properties of various estrogen formulations". Am. J. Obstet. Gynecol. 144 (5): 511–518. doi:10.1016/0002-9378(82)90218-6. PMID 6291391.
- ↑ Helgason S (1982). "Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects". Acta Obstet Gynecol Scand. 61 (S107): 1–29. doi:10.3109/00016348209155333. PMID 6282033.
- ↑ Lobo RA, Nguyen HN, Eggena P, Brenner PF (February 1988). "Biologic effects of equilin sulfate in postmenopausal women" (PDF). Fertil. Steril. 49 (2): 234–8. doi:10.1016/S0015-0282(16)59708-8. PMID 3338581.